Regeneron’s Eylea Stumbles as FDA Issues CRL for New Dosing LabelAllbiopro2018-08-14T00:35:16+09:008월 14th, 2018|
Alnylam vows value-based pricing, financial help with $450K Onpattro launchAllbiopro2018-08-14T00:34:23+09:008월 14th, 2018|
Outcome’s image rehab rolls on with Nielsen deal for first-ever POC audience talliesAllbiopro2018-08-14T00:33:56+09:008월 14th, 2018|
Genentech Snags Breakthrough Therapy Designation for Food Allergy TreatmentAllbiopro2018-08-14T00:33:28+09:008월 14th, 2018|
Salix, US WorldMeds eye 2019 push into the mainstream for opioid withdrawal drug LucemyraAllbiopro2018-08-14T00:33:01+09:008월 14th, 2018|
Alnylam Receives FDA Approval for First-Ever RNA Interference TherapeuticAllbiopro2018-08-14T00:32:33+09:008월 14th, 2018|
Izana starts proof-of-concept trial for spinal arthritis drugAllbiopro2018-08-14T00:32:05+09:008월 14th, 2018|
Researchers Debate on Whether CRISPR Works in EmbryosAllbiopro2018-08-14T00:31:38+09:008월 14th, 2018|
Fresh from GSK deal, Orchard raises $150M for multifront late-phase gene therapy pushAllbiopro2018-08-14T00:31:12+09:008월 14th, 2018|
Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy PipelineAllbiopro2018-08-14T00:30:44+09:008월 14th, 2018|
Mustang Bio picks up St. Jude’s ‘bubble boy’ gene therapyAllbiopro2018-08-14T00:30:15+09:008월 14th, 2018|
